Research Overview

Dr. Brendel collaborates with other investigators to develop novel viral vectors and virus-like particles (VLP) for HSC-targeted delivery. Key challenges include delivery specificity and efficiency, particle stability in serum, mitigating immune responses to vector or transgene, and conferring a selective advantage to gene-modified cells. Dr. Brendel's laboratory utilizes these tools to explore novel gene therapy approaches for rare diseases, including Sickle Cell Disease (SCD), Very Early Onset Inflammatory Bowel Disease (IL10-receptor deficiency) and Shwachman-Diamond Syndrome. 

Dr. Brendel's work has contributed to the development and clinical translation of two novel gene therapies for patients with severe diseases lacking alternative treatments. He has also trained numerous junior researchers who remain in the field, and advanced new disease targets and delivery methods to expand the reach of gene therapy. His ongoing research aims to develop and deploy novel tools to bring cell and gene therapy-based treatments to patients with unmet therapeutic need. 

Research Background

Dr. Christian Brendel completed his Ph.D. and postdoctoral training in Frankfurt, Germany (2005–2012), where he developed strategies to address key limitations of viral vector systems, including transgene silencing, expression specificity, and genotoxicity. 
In 2013, he joined Dr. David A. Williams' laboratory at Boston Children's Hospital (BCH) to develop a gene therapy for sickle cell disease (SCD), pursuing a novel RNAi-based strategy to deplete BCL11A, a repressor of fetal hemoglobin expression. Dr. Brendel and his colleagues identified an essential role for BCL11A in HSC engraftment and self-renewal, optimized the therapeutic hairpin RNA, and developed an improved lentiviral producer cell line, yielding numurous publications and awards. In 2017, Dr. Brendel was appointed Assistant Professor at Harvard Medical School, with his laboratory based in the Gene Therapy Program at Boston Children's Hospital (BCH) and Dana-Farber Cancer Institute (DFCI). 

Since 2017, the Brendel laboratory has focused on viral vector-based delivery for direct in vivo gene transfer targeting HSCs and delivering chimeric antigen receptors to T cells. This emerging field is central to making gene therapy safer, more accessible, and more affordable. With funding from the Bill & Melinda Gates Foundation and the NIH, Dr. Brendel collaborates with other investigators to develop novel viral vectors and virus-like particles (VLP) for HSC-targeted delivery. Based on this work, Dr. Brendel was invited to join a scientific advisory council formed by the Genome Editing Institute and the American Society of Hematology to help develop NIH guidelines. 

Publications

  1. Systemic delivery of phagocytosis-shielded retroviral vectors enables in vivo HSC gene therapy for sickle cell disease. Cell Stem Cell. 2026 Oct 01; 33(10):1643-1657.e5. View Abstract
  2. Non-genotoxic transplantation and in vivo selection through epitope editing. Nature. 2026 Sep; 657(8130):262-274. View Abstract
  3. Optimized lentivirus-derived virus-like particles for efficient delivery of Cas9-based genome editors. Nucleic Acids Res. 2026 May 20; 54(10). View Abstract
  4. Transduction of Quiescent Human Hematopoietic Stem and Progenitor Cells Using Lentiviral Vectors and Virus-Like Particles. Curr Protoc. 2026 Jan; 6(1):e70301. View Abstract
  5. Modeling integration site data for safety assessment with MELISSA. Nat Commun. 2025 Aug 23; 16(1):7868. View Abstract
  6. Have we really solved rAAV6 toxicity? A closer look at mannose-coupled rAAV6 vectors. Mol Ther Nucleic Acids. 2025 Sep 09; 36(3):102603. View Abstract
  7. Correction: Weber et al. Stat5 Exerts Distinct, Vital Functions in the Cytoplasm and Nucleus of Bcr-Abl+ K562 and Jak2(V617F)+ HEL Leukemia Cells. Cancers 2015, 7, 503-537. Cancers (Basel). 2025 May 23; 17(11). View Abstract
  8. Gene editing without ex vivo culture evades genotoxicity in human hematopoietic stem cells. Cell Stem Cell. 2025 02 06; 32(2):191-208.e11. View Abstract
  9. UM171 enhances fitness and engraftment of gene-modified hematopoietic stem cells from patients with sickle cell disease. Blood Adv. 2024 Nov 26; 8(22):5885-5895. View Abstract
  10. Engineered packaging cell line for the enhanced production of baboon-enveloped retroviral vectors. Mol Ther Nucleic Acids. 2024 Dec 10; 35(4):102389. View Abstract
  11. Scalable assessment of genome editing off-targets associated with genetic variants. bioRxiv. 2024 Jul 25. View Abstract
  12. Engineering an inducible leukemia-associated fusion protein enables large-scale ex vivo production of functional human phagocytes. Proc Natl Acad Sci U S A. 2024 06 18; 121(25):e2312499121. View Abstract
  13. A novel high-titer, bifunctional lentiviral vector for autologous hematopoietic stem cell gene therapy of sickle cell disease. Mol Ther Methods Clin Dev. 2024 Jun 13; 32(2):101254. View Abstract
  14. Genetic reversal of the globin switch concurrently modulates both fetal and sickle hemoglobin and reduces red cell sickling. Nat Commun. 2023 09 20; 14(1):5850. View Abstract
  15. Epitope editing enables targeted immunotherapy of acute myeloid leukaemia. Nature. 2023 09; 621(7978):404-414. View Abstract
  16. Swapping the serotype: A novel helper-dependent adenoviral vector platform for in vivo HSC gene therapy. Mol Ther Methods Clin Dev. 2023 Sep 14; 30:14-15. View Abstract
  17. Gene editing without ex vivo culture evades genotoxicity in human hematopoietic stem cells. bioRxiv. 2023 May 27. View Abstract
  18. Topological phonon transport in an optomechanical system. Nat Commun. 2022 Jun 17; 13(1):3476. View Abstract
  19. Economic Impact of COVID-19 Pandemic on Dental Practices in Germany: A Cross-Sectional Survey. Int J Environ Res Public Health. 2022 05 28; 19(11). View Abstract
  20. Development of a double shmiR lentivirus effectively targeting both BCL11A and ZNF410 for enhanced induction of fetal hemoglobin to treat ß-hemoglobinopathies. Mol Ther. 2022 08 03; 30(8):2693-2708. View Abstract
  21. Deletion of murine Rhoh leads to de-repression of Bcl-6 via decreased KAISO levels and accelerates a malignancy phenotype in a murine model of lymphoma. Small GTPases. 2022 01; 13(1):267-281. View Abstract
  22. Restored Macrophage Function Ameliorates Disease Pathophysiology in a Mouse Model for IL10 Receptor-deficient Very Early Onset Inflammatory Bowel Disease. J Crohns Colitis. 2021 Sep 25; 15(9):1588-1595. View Abstract
  23. Distinct genetic pathways define pre-malignant versus compensatory clonal hematopoiesis in Shwachman-Diamond syndrome. Nat Commun. 2021 02 26; 12(1):1334. View Abstract
  24. Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease. N Engl J Med. 2021 01 21; 384(3):205-215. View Abstract
  25. Innovative Therapies for Hemoglobin Disorders. BioDrugs. 2020 Oct; 34(5):625-647. View Abstract
  26. Current and future gene therapies for hemoglobinopathies. Curr Opin Hematol. 2020 05; 27(3):149-154. View Abstract
  27. Preclinical Evaluation of a Novel Lentiviral Vector Driving Lineage-Specific BCL11A Knockdown for Sickle Cell Gene Therapy. Mol Ther Methods Clin Dev. 2020 Jun 12; 17:589-600. View Abstract
  28. Differential Transgene Silencing of Myeloid-Specific Promoters in the AAVS1 Safe Harbor Locus of Induced Pluripotent Stem Cell-Derived Myeloid Cells. Hum Gene Ther. 2020 02; 31(3-4):199-210. View Abstract
  29. Humanized mice are precious tools for evaluation of hematopoietic gene therapies and preclinical modeling to move towards a clinical trial. Biochem Pharmacol. 2020 04; 174:113711. View Abstract
  30. Highly efficient therapeutic gene editing of human hematopoietic stem cells. Nat Med. 2019 May; 25(5):776-783. View Abstract
  31. Editing aberrant splice sites efficiently restores ß-globin expression in ß-thalassemia. Blood. 2019 05 23; 133(21):2255-2262. View Abstract
  32. Compatibility of RUNX1/ETO fusion protein modules driving CD34+ human progenitor cell expansion. Oncogene. 2019 01; 38(2):261-272. View Abstract
  33. DROSHA Knockout Leads to Enhancement of Viral Titers for Vectors Encoding miRNA-Adapted shRNAs. Mol Ther Nucleic Acids. 2018 Sep 07; 12:591-599. View Abstract
  34. Non-Clinical Efficacy and Safety Studies on G1XCGD, a Lentiviral Vector for Ex Vivo Gene Therapy of X-Linked Chronic Granulomatous Disease. Hum Gene Ther Clin Dev. 2018 06; 29(2):69-79. View Abstract
  35. Curative approaches for sickle cell disease: A review of allogeneic and autologous strategies. Blood Cells Mol Dis. 2017 09; 67:155-168. View Abstract
  36. Photocrosslinkable polysaccharide hydrogel composites based on dextran or pullulan-amylose blends with cytokines for a human co-culture model of human osteoblasts and endothelial cells. J Mater Chem B. 2016 Oct 28; 4(40):6552-6564. View Abstract
  37. Lineage-specific BCL11A knockdown circumvents toxicities and reverses sickle phenotype. J Clin Invest. 2016 10 03; 126(10):3868-3878. View Abstract
  38. RhoH participates in a multi-protein complex with the zinc finger protein kaiso that regulates both cytoskeletal structures and chemokine-induced T cells. Small GTPases. 2018 05 04; 9(3):260-273. View Abstract
  39. Mathematical modeling of erythrocyte chimerism informs genetic intervention strategies for sickle cell disease. Am J Hematol. 2016 09; 91(9):931-7. View Abstract
  40. Surface Functionalization of Orthopedic Titanium Implants with Bone Sialoprotein. PLoS One. 2016; 11(4):e0153978. View Abstract
  41. Topological phase transitions and chiral inelastic transport induced by the squeezing of light. Nat Commun. 2016 Mar 02; 7:10779. View Abstract
  42. Hyperinflammation in patients with chronic granulomatous disease leads to impairment of hematopoietic stem cell functions. J Allergy Clin Immunol. 2016 07; 138(1):219-228.e9. View Abstract
  43. Group therapy task training versus individual task training during inpatient stroke rehabilitation: a randomised controlled trial. Clin Rehabil. 2016 Jul; 30(7):637-48. View Abstract
  44. Pattern phase diagram for two-dimensional arrays of coupled limit-cycle oscillators. Phys Rev E Stat Nonlin Soft Matter Phys. 2015 Jul; 92(1):012902. View Abstract
  45. miRNA-embedded shRNAs for Lineage-specific BCL11A Knockdown and Hemoglobin F Induction. Mol Ther. 2015 Sep; 23(9):1465-74. View Abstract
  46. Stat5 Exerts Distinct, Vital Functions in the Cytoplasm and Nucleus of Bcr-Abl+ K562 and Jak2(V617F)+ HEL Leukemia Cells. Cancers (Basel). 2015 Mar 19; 7(1):503-37. View Abstract
  47. A minimal ubiquitous chromatin opening element (UCOE) effectively prevents silencing of juxtaposed heterologous promoters by epigenetic remodeling in multipotent and pluripotent stem cells. Nucleic Acids Res. 2015 Feb 18; 43(3):1577-92. View Abstract
  48. CD105 is a surface marker for receptor-targeted gene transfer into human long-term repopulating hematopoietic stem cells. Stem Cells Dev. 2015 Mar 15; 24(6):714-23. View Abstract
  49. Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor. Mol Ther. 2015 Feb; 23(2):330-8. View Abstract
  50. CD133-targeted gene transfer into long-term repopulating hematopoietic stem cells. Mol Ther. 2015 Jan; 23(1):63-70. View Abstract
  51. Generation of X-CGD cells for vector evaluation from healthy donor CD34(+) HSCs by shRNA-mediated knock down of gp91(phox). Mol Ther Methods Clin Dev. 2014; 1:14037. View Abstract
  52. Unexpected help: mTOR meets lentiviral vectors. Blood. 2014 Aug 07; 124(6):832-3. View Abstract
  53. Reduced fibroblast adhesion and proliferation on plasma-modified titanium surfaces. J Mater Sci Mater Med. 2014 Nov; 25(11):2549-60. View Abstract
  54. Erbb2/Her2-specific natural killer cells for adoptive immunotherapy of glioblastoma. Neuro Oncol. 2014 Jul; 16 Suppl 3:iii44. View Abstract
  55. Retroviral transduction of murine and human hematopoietic progenitors and stem cells. Methods Mol Biol. 2014; 1185:287-309. View Abstract
  56. The inhibition of stat5 by a Peptide aptamer ligand specific for the DNA binding domain prevents target gene transactivation and the growth of breast and prostate tumor cells. Pharmaceuticals (Basel). 2013 Aug 20; 6(8):960-87. View Abstract
  57. From bench to bedside: preclinical evaluation of a self-inactivating gammaretroviral vector for the gene therapy of X-linked chronic granulomatous disease. Hum Gene Ther Clin Dev. 2013 Jun; 24(2):86-98. View Abstract
  58. Human miR223 promoter as a novel myelo-specific promoter for chronic granulomatous disease gene therapy. Hum Gene Ther Methods. 2013 Jun; 24(3):151-9. View Abstract
  59. Transient Expression of an LEDGF/p75 Chimera Retargets Lentivector Integration and Functionally Rescues in a Model for X-CGD. Mol Ther Nucleic Acids. 2013 Mar 05; 2:e77. View Abstract
  60. A ubiquitous chromatin opening element prevents transgene silencing in pluripotent stem cells and their differentiated progeny. Stem Cells. 2013 Mar; 31(3):488-99. View Abstract
  61. Alpharetroviral vector-mediated gene therapy for X-CGD: functional correction and lack of aberrant splicing. Mol Ther. 2013 Mar; 21(3):648-61. View Abstract
  62. Safer, silencing-resistant lentiviral vectors: optimization of the ubiquitous chromatin-opening element through elimination of aberrant splicing. J Virol. 2012 Sep; 86(17):9088-95. View Abstract
  63. Physiological regulation of transgene expression by a lentiviral vector containing the A2UCOE linked to a myeloid promoter. Gene Ther. 2012 Oct; 19(10):1018-29. View Abstract
  64. Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells. Mol Ther. 2011 Jan; 19(1):122-32. View Abstract
  65. Survival of the fittest: positive selection of CD4+ T cells expressing a membrane-bound fusion inhibitor following HIV-1 infection. PLoS One. 2010 Aug 23; 5(8):e12357. View Abstract
  66. Mammary epithelial reconstitution with gene-modified stem cells assigns roles to Stat5 in luminal alveolar cell fate decisions, differentiation, involution, and mammary tumor formation. Stem Cells. 2010 May; 28(5):928-38. View Abstract

Contact Christian Brendel